Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
THOUSAND OAKS, Calif. – Amgen Inc. says its second-quarter net income rose 8 per cent as the world’s largest biotech company posted higher sales for its top-selling drug and two new ones added to revenue.
The results were far above Wall Street expectations.
The maker of osteoporosis drug Prolia and Enbrel for inflammatory disorders says net income was $1.27 billion, or $1.61 per share, up from $1.17 billion, or $1.25 per share, a year earlier.
Excluding one-time items, Amgen says net income was $1.43 billion, or $1.83 per share, up from $1.28 billion, or $1.37 per share, in 2011’s second quarter.
Revenue totalled $4.48 billion, up 13 per cent.
Analysts were expecting, on average, earnings per share of $1.54, excluding one-time items, and revenue of $4.08 billion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.